Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Top-Seller Humira Set for U.S. Rival After $193 Billion in Sales

April 1, 2022, 2:00 PM

AbbVie Inc. made its arthritis treatment Humira the best-selling medication in the world. Now, after years of wrangling, rivals are finally set to bring a wave of lower-cost versions to the U.S.

The arrival of the Humira copycats will be a pivotal test for a class of treatments that advocates have long said could help fence in runaway drug costs. Biosimilars -- cheaper versions of complicated treatments made from living cells -- remain a relatively small market in the U.S., in part because makers of big-name biologic drugs have fought hard to protect them from competition.

Humira is the biggest ...